Strategic Scientific Communications Fellowship

For Ph.D. professionals in the life sciences, the Strategic
Scientific Communications Fellowship is an opportunity to jumpstart
your career while delivering life-changing information to colleagues
and customers.

The Strategic Scientific Communications (SSC) group creates
clinical, scientific and regulatory documents that advance the medical
and educational initiatives of Novo Nordisk. We take pride in
producing balanced and scientifically accurate publications that
adhere to the highest ethical and quality standards. Over the course
of the one-year Fellowship experience, Fellows learn and engage in the
following activities:

Understand the role and
responsibilities of a medical writer

Learn and adhere to
guidelines for ethical publication practice

Provide medical
writing support to authors in the development of scientific
publications and presentations

Perform medical accuracy
review of supplements and articles

Coordinate internal
medical review and author review of publications

Assist SSC
members in the preparation of regulatory documents such as clinical
trial reports and clinical summary documents

Who We're Looking For

We are seeking candidates with a doctorate degree (Ph.D.) in the
life sciences with a demonstrated expertise in scientific writing,
including manuscripts and research grant documents. Bring your
knowledge of statistical methods, plus your ability to understand
regulatory requirements related to the drug development process.
Candidates must exhibit attention to detail, deep scientific knowledge
and a passion for delivering high-quality communications.

Novo
Nordisk USA

Headquartered in Denmark, Novo Nordisk is a global healthcare
company with 95 years of innovation and leadership in diabetes care.
This heritage has given us experience and capabilities that also
enable us to help people defeat other serious chronic conditions: rare
bleeding disorders, growth hormone-related disorders, and obesity.

All personal information reported in relation
to a complaint or a side effect will be processed in accordance with
applicable data protection legislation. For avoidance of doubt, “data
protection legislation” means the law governing the Novo Nordisk
entity receiving the complaint or report, not the residence or
location of the individual data subject submitting the report or
complaint:

Your report is used solely for the scientific evaluation of
the medicine and product quality.

Side effects are filed in
our global safety database and the data is regularly analyzed for
overall patterns.

Novo Nordisk may share reported
complaints and side effects with health authorities as mandated by
law, regulation or as required by court order.

Novo Nordisk
will retain the data consistent with Novo Nordisk’s data retention
policies and as long as required by law.